SK4592001A3 - Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition - Google Patents
Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition Download PDFInfo
- Publication number
- SK4592001A3 SK4592001A3 SK459-2001A SK4592001A SK4592001A3 SK 4592001 A3 SK4592001 A3 SK 4592001A3 SK 4592001 A SK4592001 A SK 4592001A SK 4592001 A3 SK4592001 A3 SK 4592001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- atypical antipsychotic
- patients suffering
- antipsychotic agent
- active ingredient
- acetylcholinesterase
- Prior art date
Links
- 239000003693 atypical antipsychotic agent Substances 0.000 title claims abstract description 24
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims abstract description 13
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title claims abstract description 12
- 230000019771 cognition Effects 0.000 title abstract 2
- 229940127236 atypical antipsychotics Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 239000003112 inhibitor Substances 0.000 claims abstract description 21
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 17
- 206010012289 Dementia Diseases 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 16
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 10
- 230000002411 adverse Effects 0.000 claims abstract description 9
- 230000009286 beneficial effect Effects 0.000 claims abstract description 7
- 230000006866 deterioration Effects 0.000 claims abstract description 4
- 230000002195 synergetic effect Effects 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000003920 cognitive function Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 10
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 10
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 10
- 229960003980 galantamine Drugs 0.000 claims description 9
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960001534 risperidone Drugs 0.000 claims description 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960003162 iloperidone Drugs 0.000 claims description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004431 quetiapine Drugs 0.000 claims description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 206010067484 Adverse reaction Diseases 0.000 claims 1
- 230000006838 adverse reaction Effects 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- -1 hydrohalic acids Chemical class 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 | ||
| PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK4592001A3 true SK4592001A3 (en) | 2001-12-03 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK459-2001A SK4592001A3 (en) | 1998-10-16 | 1999-10-12 | Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (de) |
| JP (1) | JP2002527469A (de) |
| KR (1) | KR20010072878A (de) |
| CN (1) | CN1367697A (de) |
| AU (1) | AU6472799A (de) |
| BG (1) | BG105302A (de) |
| BR (1) | BR9914419A (de) |
| CA (1) | CA2345767A1 (de) |
| EE (1) | EE200100136A (de) |
| HK (1) | HK1039745A1 (de) |
| HR (1) | HRP20010262A2 (de) |
| HU (1) | HUP0103781A3 (de) |
| ID (1) | ID28441A (de) |
| IL (1) | IL142588A0 (de) |
| NO (1) | NO20011403L (de) |
| PL (1) | PL348107A1 (de) |
| SK (1) | SK4592001A3 (de) |
| TR (1) | TR200101082T2 (de) |
| WO (1) | WO2000023057A2 (de) |
| ZA (1) | ZA200103081B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| BRPI0213564B8 (pt) | 2001-10-30 | 2021-05-25 | Novartis Ag | formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2006065233A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (de) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
| MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
| AU2011215870B2 (en) | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| JP4640888B2 (ja) * | 1997-08-11 | 2011-03-02 | ザ ユニヴァーシティー オブ サウス フロリダ | 神経精神性疾患用ニコチンアンタゴニスト |
| EP1073432B1 (de) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie |
-
1999
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Ceased
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Withdrawn
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/de not_active Withdrawn
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 HK HK02100158.6A patent/HK1039745A1/zh unknown
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000023057A3 (en) | 2000-07-27 |
| TR200101082T2 (tr) | 2001-09-21 |
| HRP20010262A2 (en) | 2002-06-30 |
| HUP0103781A2 (hu) | 2002-03-28 |
| HK1039745A1 (zh) | 2002-05-10 |
| NO20011403D0 (no) | 2001-03-20 |
| CN1367697A (zh) | 2002-09-04 |
| WO2000023057A2 (en) | 2000-04-27 |
| HUP0103781A3 (en) | 2003-09-29 |
| AU6472799A (en) | 2000-05-08 |
| CA2345767A1 (en) | 2000-04-27 |
| BR9914419A (pt) | 2001-06-26 |
| NO20011403L (no) | 2001-03-20 |
| EP1121131A2 (de) | 2001-08-08 |
| BG105302A (en) | 2001-11-30 |
| KR20010072878A (ko) | 2001-07-31 |
| IL142588A0 (en) | 2002-03-10 |
| PL348107A1 (en) | 2002-05-06 |
| ID28441A (id) | 2001-05-24 |
| ZA200103081B (en) | 2002-07-12 |
| JP2002527469A (ja) | 2002-08-27 |
| EE200100136A (et) | 2002-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK4592001A3 (en) | Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition | |
| US5945416A (en) | Method for treating pain | |
| US8404703B2 (en) | Medicinal compositions containing aspirin | |
| DE60009697T2 (de) | Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie | |
| ES2214632T3 (es) | Composicion farmaceutica antitrombotica y antiaterogena que comprende un derivado de tienopiridina y un inhibidor de la hmg-coa reductasa. | |
| US6319927B1 (en) | Method of using levocetirizine and pharmaceutical compositions containing the same for inducing sleep | |
| CA2449952A1 (en) | Medicinal composition | |
| EP2389937B1 (de) | Medizinische Zusammensetzungen zur Verbesserung der Hirnfunktion | |
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| JP2001517202A (ja) | 痛み処置方法 | |
| JP2005501108A (ja) | 神経変性治療におけるネフィラセタムの使用 | |
| RU2023449C1 (ru) | Способ стабилизации 4-этил-2-гидроксиимино-5-нитро-3-гексенамида | |
| SK5082001A3 (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 | |
| CA1209047A (en) | Therapeutic composition containing piracetam analog | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| EP0671908B1 (de) | Pharmazeutische zusammensetzungen, die 5-ht 1-rezeptoragonisten und absorptionsverstärker enthalten | |
| RU2001113270A (ru) | Лечение, направленное на улучшение познавательной способности | |
| JPH09104662A (ja) | 光に安定なベンジルアルコール誘導体含有水溶液 | |
| KR20060130689A (ko) | 인지 기능의 감퇴를 억제하기 위한 혼합 약제 조성물 | |
| HK1128621A (en) | Diaryl urea for treating pulmonary hypertension | |
| BG65206B1 (bg) | Естери на (+)-алфа-(2,3-диметоксифенил)-1-[2-(4-флуорoфенил)етил]-4- пиперидинметанол, метод за тяхното получаване и приложението им като предшественици на 5ht2a рецепторния антагонист mdl 110,907 | |
| HUT70439A (en) | Injectable solution for administration of one or more active compounds in situ and process for its preparation |